Ophthalmic Business News

Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, with the aim of expanding its position in the gene therapy space for the treatment of inherited retinal diseases, according to a press release.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Douglas Love, president and CEO of Annexon Biosciences, discusses the company’s phase 3 program in geographic atrophy.

Nonqualified plans offer a valuable alternative or supplement to qualified retirement plans for physicians seeking to enhance their retirement savings.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the next steps for the phase 3 SOL-1 and SOL-R studies.

Scope Health announced its acquisition of Eyetamins, an eye health supplement brand created by neuro-ophthalmologist Kaushal Kulkarni, MD, according to a press release.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Calvin Roberts, MD, program manager at the Advanced Research Projects Agency for Health, discusses two “moonshot” ophthalmology programs from the organization.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Rob Sambursky, MD, president of Verséa Ophthalmics, discusses the company’s offerings for ocular wound healing and ocular surface diseases.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Patrick Mooney, CEO of Spyglass Pharma, discusses the company’s IOL-based bimatoprost drug delivery platform for patients with open-angle glaucoma or ocular hypertension.

CHICAGO — Collaborations and consolidations within the eye care space will be potentially disruptive over the next 5 years, according to a market expert at Eyecelerator@AAO.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Greg Kunst of Aurion Biotech provides an update on the company’s cell therapy for corneal endothelial disease.